title: [Results of treatment of far advanced and recurrent stomach cancer with TS-1].
abstract: We used TS-1 as first-line therapy to treat 44 patients with far advanced or recurrent gastric cancer, and assessed the results and safety. One treatment cycle consisted of TS-1, 80 mg/m2/day, for 28 days followed by a 14-day rest period. The efficacy rate in the cases capable of being evaluated was 30.1% (11/36), and 25.0%, (7/28) when TS-1 was used as monotherapy. The efficacy rate was lower than in a phase II study, however, the median survival time (MST) of 10.7 months for the patients as a whole, the 1-year survival rate of 43.2%, and the 2-year survival rate of 20.5% were favorable. There were many NC cases in which long-term therapy was possible, and they contributed to the long-term survival. The incidence of adverse events was 84.1%, but the incidence of grade 3 or more events was low at 13.6%. Since TS-1 is highly efficacious and safe, as well as convenient because of being an oral preparation, it appears that it can be ranked as the drug of first choice for chemotherapy of far advanced or recurrent gastric cancer.
authors.affiliation: Dept of Surgery, Matsuyama Shimin Hospital.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Johira
authors.forename: Shigeru
authors.initials: S
authors.lastname: Yunoki
authors.forename: Naomi
authors.initials: N
authors.lastname: Kawata
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Watanabe
authors.forename: Yasuki
authors.initials: Y
authors.lastname: Hachisuka
authors.forename: Masashi
authors.initials: M
authors.lastname: Kimura
authors.forename: Masashi
authors.initials: M
authors.lastname: Uomoto
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Hatano
authors.forename: Eiji
authors.initials: E
authors.lastname: Sanada
authors.forename: Ryouhei
authors.initials: R
authors.lastname: Watanabe
authors.forename: Katsusuke
authors.initials: K
authors.lastname: Ohmori
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Miyata
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000855:Anorexia / Q000139:chemically induced; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid